NBRV
Income statement / Annual
Last year (2022), Nabriva Therapeutics plc's total revenue was $35.67 M,
an increase of 31.06% from the previous year.
In 2022, Nabriva Therapeutics plc's net income was -$57.19 M.
See Nabriva Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$35.67 M
|
$27.22 M
|
$2.86 M
|
$7.75 M
|
$6.50 M
|
$0.00
|
$0.00
|
$84,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$28.58 M |
$13.15 M |
$766,000.00 |
$70,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$7.09 M |
$14.07 M |
$2.10 M |
$7.68 M |
$6.50 M |
$0.00 |
$0.00 |
$84,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.2 |
0.52 |
0.73 |
0.99 |
1 |
0 |
0 |
1 |
0 |
0 |
| Research and Development
Expenses |
$14.26 M
|
$12.63 M
|
$15.10 M
|
$26.42 M
|
$82.29 M
|
$49.62 M
|
$47.99 M
|
$22.73 M
|
$8.59 M
|
$10.11 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$41.74 M
|
$29.47 M
|
$13.44 M
|
$7.82 M
|
$3.46 M
|
$3.91 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$45.26 M
|
$51.65 M
|
$55.29 M
|
$62.49 M
|
$41.74 M
|
$29.47 M
|
$13.44 M
|
$7.82 M
|
$3.46 M
|
$3.91 M
|
| Other Expenses |
-$1.27 M |
-$1.68 M |
-$2.16 M |
-$1.73 M |
-$272,000.00 |
$492,000.00 |
$55,000.00 |
$2.86 M |
$77,824.00 |
$34.30 M |
| Operating Expenses |
$58.26 M |
$62.60 M |
$68.22 M |
$87.17 M |
$120.88 M |
$73.77 M |
$55.05 M |
$26.84 M |
$9.89 M |
$6.74 M |
| Cost And Expenses |
$86.84 M |
$75.74 M |
$68.99 M |
$87.24 M |
$120.88 M |
$73.77 M |
$55.05 M |
$26.84 M |
$9.89 M |
$6.74 M |
| Interest Income |
$0.00 |
$0.00 |
$86,000.00 |
$255,000.00 |
$49,000.00 |
$318,000.00 |
$343,000.00 |
$6.74 M |
$2,432.02 |
$307,934.00 |
| Interest Expense |
$698,000.00 |
$0.00 |
$1.74 M |
$3.64 M |
$133,000.00 |
$43,000.00 |
$75,000.00 |
$14.59 M |
$6.98 M |
$5.55 M |
| Depreciation &
Amortization |
-$3.53 M
|
$637,000.00
|
$1.27 M
|
$470,000.00
|
$510,000.00
|
$432,000.00
|
$233,000.00
|
$150,875.00
|
$152,001.00
|
$197,464.00
|
| EBITDA |
-$54.70 M
|
-$48.53 M
|
-$64.85 M
|
-$79.02 M
|
-$114.09 M
|
-$72.53 M
|
-$54.42 M
|
-$17.24 M
|
-$9.75 M
|
$28.06 M
|
| EBITDA Ratio |
-1.53 |
-1.78 |
-22.64 |
-10.2 |
-17.55 |
0 |
0 |
-205.19 |
0 |
0 |
| Operating Income Ratio
|
-1.43
|
-1.78
|
-23.09
|
-10.26
|
-17.6
|
0
|
0
|
-285.44
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$4.44 M
|
-$432,000.00
|
-$3.22 M
|
-$3.17 M
|
-$356,000.00
|
$767,000.00
|
-$515,000.00
|
$2.86 M
|
-$6.42 M
|
-$5.76 M
|
| Income Before Tax |
-$55.62 M |
-$48.96 M |
-$69.35 M |
-$82.66 M |
-$114.73 M |
-$73.00 M |
-$55.56 M |
-$31.82 M |
-$16.18 M |
$16.55 M |
| Income Before Tax Ratio
|
-1.56
|
-1.8
|
-24.21
|
-10.67
|
-17.65
|
0
|
0
|
-378.87
|
0
|
0
|
| Income Tax Expense |
$1.57 M |
$490,000.00 |
$139,000.00 |
$101,000.00 |
$49,000.00 |
$1.36 M |
-$672,000.00 |
-$438,414.27 |
$87,552.00 |
$1.07 M |
| Net Income |
-$57.19 M |
-$49.45 M |
-$69.48 M |
-$82.76 M |
-$114.78 M |
-$74.36 M |
-$54.89 M |
-$31.39 M |
-$16.27 M |
$15.48 M |
| Net Income Ratio |
-1.6 |
-1.82 |
-24.26 |
-10.68 |
-17.66 |
0 |
0 |
-373.65 |
0 |
0 |
| EPS |
-21.32 |
-28.52 |
-135.23 |
-278.86 |
-564.91 |
-623.15 |
-638.9 |
-741.38 |
-149.52 |
142.25 |
| EPS Diluted |
-21.32 |
-28.52 |
-135.23 |
-278.86 |
-564.91 |
-623.15 |
-638.9 |
-741.38 |
-149.52 |
130.92 |
| Weighted Average Shares
Out |
$2.68 M
|
$1.73 M
|
$513,804.00
|
$296,797.00
|
$203,183.00
|
$119,322.00
|
$85,913.00
|
$42,335.00
|
$108,816.00
|
$108,816.00
|
| Weighted Average Shares
Out Diluted |
$2.68 M
|
$1.73 M
|
$513,804.00
|
$296,797.00
|
$203,183.00
|
$119,322.00
|
$85,913.00
|
$42,335.00
|
$108,816.00
|
$108,816.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
